These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
264 related items for PubMed ID: 11225517
1. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions. Tekes K, Magyar K. Neurobiology (Bp); 2000; 8(3-4):257-64. PubMed ID: 11225517 [Abstract] [Full Text] [Related]
2. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Tekes K, Tóthfalusi L, Gaál J, Magyar K. Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003 [Abstract] [Full Text] [Related]
3. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Knoll J, Miklya I. Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186 [Abstract] [Full Text] [Related]
4. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I, Youdim MB, Finberg JP. J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937 [Abstract] [Full Text] [Related]
5. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB. Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351 [Abstract] [Full Text] [Related]
6. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. Knoll J. J Neural Transm Suppl; 1987 Jun 29; 25():45-66. PubMed ID: 2828537 [Abstract] [Full Text] [Related]
7. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508]. Miklya I. Neuropsychopharmacol Hung; 2008 Mar 29; 10(1):15-22. PubMed ID: 18771016 [Abstract] [Full Text] [Related]
8. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A. Kagaya T, Kajiwara A, Nagato S, Akasaka K, Kubota A. J Pharmacol Exp Ther; 1996 Jul 29; 278(1):243-51. PubMed ID: 8764357 [Abstract] [Full Text] [Related]
9. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Gal S, Zheng H, Fridkin M, Youdim MB. J Neurochem; 2005 Oct 29; 95(1):79-88. PubMed ID: 16181414 [Abstract] [Full Text] [Related]
10. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. Löscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G. J Pharmacol Exp Ther; 1999 Mar 29; 288(3):984-92. PubMed ID: 10027835 [Abstract] [Full Text] [Related]
11. High-throughput screening for monoamine oxidase-A and monoamine oxidase-B inhibitors using one-step fluorescence assay. Guang HM, Du GH. Acta Pharmacol Sin; 2006 Jun 29; 27(6):760-6. PubMed ID: 16723097 [Abstract] [Full Text] [Related]
12. [Effect of solubilization by methylethylketone of rat liver mitochondrial monoamine oxidase on inhibition by clorgyline and deprenyl of the enzyme activity]. Severina IS, Klimova GI, Nersisian AA. Biokhimiia; 1981 Nov 29; 46(11):2043-55. PubMed ID: 6797482 [Abstract] [Full Text] [Related]
13. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity. Yáñez M, Fraiz N, Cano E, Orallo F. Eur J Pharmacol; 2006 Aug 07; 542(1-3):54-60. PubMed ID: 16828740 [Abstract] [Full Text] [Related]
14. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl. Karoum F. Br J Pharmacol; 1987 Feb 07; 90(2):335-45. PubMed ID: 3103805 [Abstract] [Full Text] [Related]
15. [Effect of protein denaturing reactions on retardation of the activity of rat liver mitochondrial monoamine oxidase by clorgyline and deprenyl]. Severina IS. Biokhimiia; 1983 Sep 07; 48(9):1513-21. PubMed ID: 6414536 [Abstract] [Full Text] [Related]
16. Effects of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats. Timár J, Knoll B, Gyarmati Z, Knoll J. Pol J Pharmacol Pharm; 1979 Sep 07; 31(4):251-60. PubMed ID: 523335 [Abstract] [Full Text] [Related]
17. L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action. He S, Grasing K. Pharmacol Biochem Behav; 2006 Dec 07; 85(4):675-88. PubMed ID: 17157368 [Abstract] [Full Text] [Related]
18. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats. Kitaichi Y, Inoue T, Nakagawa S, Izumi T, Koyama T. Eur J Pharmacol; 2006 Feb 27; 532(3):236-45. PubMed ID: 16487506 [Abstract] [Full Text] [Related]
19. Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study. Nishi K, Mück-Seler D, Hasegawa S, Watanabe A, Diksic M. Brain Res Bull; 2006 Oct 16; 70(4-6):368-77. PubMed ID: 17027772 [Abstract] [Full Text] [Related]
20. Inhibition of MAO-A activity enhances behavioural activity of rats assessed using water maze and open arena tasks. Barbelivien A, Nyman L, Haapalinna A, Sirviö J. Pharmacol Toxicol; 2001 Jun 16; 88(6):304-12. PubMed ID: 11453370 [Abstract] [Full Text] [Related] Page: [Next] [New Search]